Downloading...
Download

VKTX

SPX - Are you catching the rotation trends? SPX is still holding very bullish price action. Technicals are pointing towards higher price and todays inside consolidation day certainly helps digest recent gains. Along with the flat indices market session, we did observe some massive capital rotation trends. Financials saw a pretty strong down move across the board. JPM / BAC / C all saw large outflows. We were positioned on the short side of financials and took profits on JPM puts. Even with the big selloff in financials, SPX held up surprisingly well. Capital simply rotated instead of outright leaving the market. Bullish Signal. Technology, Energy, Materials, Health care, Transports all saw capital inflow trends. Rotation into under preforming sectors is a sign that markets could be staging another healthy leg up. We still have an upside target over 6300 on SPX.
SP:SPXLong
by Trading-Capital
1
VKTX: Unusual Options Flow & a Breakthrough Weight-Loss DrugIf you haven`t bought CKTX before the recent rally: Now you need to know that Viking Therapeutics (VKTX) is a speculative biotech stock in the GLP-1/GIP agonist space, aiming to challenge market leaders like Eli Lilly and Novo Nordisk. Recently, I noticed unusual options flow — specifically, Jan 16, 2026 $60 strike calls Key Bullish Points 1) Riding the Obesity Drug Boom VK2735 is Viking’s dual agonist candidate showing promising early weight-loss efficacy, with potential overlap benefits in NASH (liver disease). The obesity treatment space is expected to exceed $100B by 2030—huge upside if their trials continue positively. 2) Options Flow Tells a Story Those Jan 2026 $60 calls caught my attention precisely because the stock currently trades in the mid-$60s. These aren’t cheap lottery plays—they’re strategically timed wrt trial readouts, partnerships, or acquisition interest. Essentially, someone anticipates meaningful upside in the near future. 3) Descending Wedge — Chart Looks Bullish VKTX peaked near $100, then pulled back into a well-defined descending wedge. If it breaks out above $70–$72 with volume, that could kick off a classic reversal trade. Smart Money Options Flow — Near-Term Bet: Recently, I spotted unusual open interest in $60 strike calls expiring Jan 16, 2026 — that’s only about 7 months away. This means someone is positioning for a big upside move relatively soon, likely betting on positive Phase 2b/3 data, a partnership deal, or even buyout chatter within the next few quarters. Short-dated, out-of-the-money call flow like this often hints at near-term news — not just a long-dated hedge.
NASDAQ:VKTXLong
by TopgOptions
$VKTX is about to FEAST! Don't miss out on this BioTech trade. 🚀 Here it is: Your Free Saturday Setup! 🚀 Just as promised, here is a detailed video analysis on NASDAQ:VKTX Viking Therapeutics! 🧬 This trade meets all the criteria of my "High Five Setup" trading strategy, backed by solid technical analysis. Also, it has the potential to return over 100% on your capital deployed. With more probabilities on our side, the likelihood of success is through the roof! 📈💥 Check it out, and let’s ride this wave together! 🌊 Stay tuned for more insights! 🔔 NFA #Trading #StockMarket #Biotech #Investing #HighFiveSetup
NASDAQ:VKTXLong
by RonnieV29
41
Viking Therapeutics Surges 25% Amidst Weight Loss Pill Data In a remarkable turn of events, Viking Therapeutics ( NASDAQ:VKTX ) has sent shockwaves through the pharmaceutical industry with groundbreaking results from its experimental weight loss pill. The company's shares soared by over 25% following the announcement of positive outcomes from a small-scale study, propelling it into the forefront of the fiercely competitive weight-loss drug market. Viking's innovative once-a-day oral tablet demonstrated remarkable efficacy in aiding weight loss among participants. Over 28 days, patients who received the pill experienced an average weight loss of up to 5.3%, significantly surpassing the outcomes of those who were administered a placebo. Notably, an impressive 57% of individuals treated with Viking's pill achieved a weight reduction of at least 5%, showcasing the drug's potential to revolutionize the treatment landscape for obesity. Moreover, the trial unveiled encouraging findings regarding the durability of weight loss, with patients maintaining or even augmenting their progress six days after the cessation of the medication. Viking's CEO, Brian Lian, underscored the significance of this sustained effect, particularly for patients facing challenges in adhering to a daily regimen. "I think that's an encouraging sign that you don't necessarily have to take it every day," remarked Lian during a conference call, hinting at the flexibility and convenience offered by Viking's pioneering approach. Crucially, the trial also provided reassuring insights into the safety and tolerability of the oral drug, with the majority of reported side effects being mild and transient. Unlike some existing treatments, patients did not report vomiting, while gastrointestinal events were predominantly mild in nature—a testament to Viking's commitment to developing a well-tolerated therapy. Analysts have drawn parallels between Viking's weight loss injection and established drugs like Eli Lilly's Zepbound, highlighting their shared mechanism of action in mimicking gut hormones involved in appetite regulation and metabolic control. By leveraging the synergistic effects of GLP-1 and GIP, Viking's pill offers a multifaceted approach to weight management, distinguishing itself in a rapidly evolving landscape. As the company sets its sights on advancing to phase two trials later this year, anticipation is palpable within the investment community and among patients seeking effective and accessible solutions for obesity. With the potential to tap into a burgeoning market projected to reach $100 billion by the end of the decade, Viking Therapeutics ( NASDAQ:VKTX ) stands poised to redefine the standard of care and carve out a niche as a formidable contender in the fight against obesity-related ailments. Technical Outlook Viking Therapeutics ( NASDAQ:VKTX ) Spiked more than 25% prior to the weight loss pill data news with a positive Relative Strength Index (RSI) of 65 indicating a moderately overbought solution with a potential for further surge. In an era marked by escalating rates of obesity and metabolic disorders, Viking's groundbreaking advancements offer a glimmer of hope for millions worldwide, signaling a new dawn in the quest for sustainable weight loss solutions. As the journey unfolds, all eyes remain fixed on Viking Therapeutics, a beacon of innovation and progress in the pursuit of healthier futures.
NASDAQ:VKTXLong
by DEXWireNews
Viking Therapeutics stock jumps 114%Shares of Viking Therapeutics ( NASDAQ:VKTX ) soared more than 114% on Tuesday after the company's experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics ( NASDAQ:VKTX ) is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say could grow into a $100 billion market by the end of the decade. But it may not join that space on its own: Analysts have suggested that larger pharmaceutical companies such as Pfizer, which scrapped two of its own weight loss drug candidates last year, could potentially move to acquire a company like Viking Therapeutics. Tuesday's share move puts Viking Therapeutics' market value at roughly $7 billion. The trial followed more than 170 patients with obesity or who are overweight, some of whom received different dose sizes of the injectable drug or a placebo. Those who received weekly doses of the treatment lost up to 14.7% of their body weight from baseline, or 13.1% when adjusted for placebo, after 13 weeks. 88% of patients who received the drug, known as VK2735, achieved at least 10% weight loss, compared with just 4% of those who didn't receive the treatment. Notably, there was no evidence of a plateau in weight reduction at week 13 for any dose of the drug, suggesting that "further weight loss might be achieved" by keeping patients on the treatment longer, Viking CEO Brian Lian said during a call with investors. The drug demonstrated "encouraging" safety in patients following the 13-week trial period. Patients also appeared to tolerate the drug well. Around 4% of patients who received any dose size of the treatment discontinued the study early compared with approximately 6% of those in the placebo group. Viking plans to present the full Phase 2 data at medical conferences. The company also said it plans to meet with the Food and Drug Administration to discuss further steps for the development of VK2735. Separately, the company said it expects to release early stage trial data on an oral version of its weight loss drug. Viking Therapeutics' ( NASDAQ:VKTX ) drug targets GLP-1 and another hormone called GIP. Those are the same hormones that Eli Lilly's weight loss and diabetes drugs, Zepbound and Mounjaro, target.
NASDAQ:VKTXLong
by DEXWireNews
2
VKTX Stock Soars to Record HighsViking Therapeutics (NASDAQ: NASDAQ:VKTX ) sent shockwaves through the biotech industry as it accelerated its timeline for a groundbreaking obesity treatment, propelling its stock to unprecedented heights. With the prospect of competing head-to-head with pharmaceutical giant Eli Lilly (NYSE: NYSE:LLY ), Viking's innovative approach promises a potential game-changer in the fight against obesity. Viking Therapeutics Surges on Accelerated Timeline In a surprising move, Viking Therapeutics announced an expedited timeline for the release of crucial data regarding its Eli Lilly-rivaling obesity treatment. The biotech firm now anticipates unveiling the results of its midstage trial for its weekly shot ahead of schedule, aligning with the imminent release of data from its oral drug study. Key Catalysts Driving Value: Leerink Partners analyst Thomas Smith underscores the significance of Viking Therapeutics' ( NASDAQ:VKTX ) accelerated catalyst path, citing multiple upcoming data readouts across obesity and NASH. Smith's bullish report emphasizes the potential for significant value inflection in VKTX shares, reflecting growing investor anticipation surrounding the company's groundbreaking developments. Viking's Dual Approach: Daily Pill and Weekly Shot Viking Therapeutics ( NASDAQ:VKTX ) is pioneering a multifaceted approach to combatting obesity, with two distinct treatment modalities in its pipeline. The company's innovative daily pill and weekly shot hold promise for addressing the diverse needs of patients battling weight-related health issues. Eli Lilly-Rivaling Potential: Implications for the Market With Viking Therapeutics ( NASDAQ:VKTX ) poised to challenge Eli Lilly in the obesity treatment arena, the biotech firm's accelerated timeline signifies a potential paradigm shift in the pharmaceutical landscape. As investors digest the implications of Viking's ambitious pursuits, industry watchers anticipate heightened competition and renewed focus on innovative solutions for obesity and related metabolic disorders. Market Response: In response to Viking Therapeutics' ( NASDAQ:VKTX ) groundbreaking updates, NASDAQ:VKTX stock surged by over 15%, reaching an all-time high of $28.10 in morning trades. The remarkable rally underscores investor confidence in the company's strategic vision and the transformative potential of its obesity treatment portfolio. Conclusion: Viking Therapeutics' ( NASDAQ:VKTX ) accelerated timeline for its Eli Lilly-rivaling obesity treatment marks a watershed moment in the biotech industry. As the company advances towards critical data readouts, the market eagerly anticipates the unfolding of a new chapter in the fight against obesity and related metabolic disorders. With NASDAQ:VKTX stock soaring to unprecedented heights, Viking's bold initiatives are poised to reshape the future of healthcare.
NASDAQ:VKTXLong
by DEXWireNews
Viking Therapeutics (VKTX): 30-40%+ Long Trade OpportunityVKTX has suffered a 10%+ decline today and I believe that there is a great long trade setup forming in the buy zone (between the two light blue trendlines). The price action is still bearish at the time of writing so I would monitor the charts for a reversal on lower time frames. However, this will be a quick trade setup for me with an exit at my sell zone between the two yellow trendlines. I believe that this will be a 30-40% trade opportunity depending on where VKTX bottoms out and peaks in these two key zones. I'm seeing a lot of bullish technical analysis signs. The two most notable are the RSI reaching oversold levels and a break below the Bollinger Band. However, I do think that VKTX has a high risk of dropping hard after reaching the yellow trendline so I'm looking to make this a quick trade.
NASDAQ:VKTXLong
by realchartchamp